STOCK TITAN

Conmed Corp Stock Price, News & Analysis

CNMD NYSE

Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.

Conmed Corporation (CNMD) delivers innovative medical technologies that enhance surgical outcomes and patient care worldwide. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate developments, financial performance, and product advancements shaping the medical device sector.

Access authoritative information on CNMD's latest earnings reports, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing new product launches in orthopedics, general surgery, and patient monitoring systems, along with updates on global market expansion initiatives.

Stay informed about critical developments through verified announcements directly from Conmed Corporation and third-party analysis. This resource enables stakeholders to track the company's progress in advancing minimally invasive surgical techniques and improving clinical workflows across healthcare institutions.

Bookmark this page for streamlined access to CNMD's evolving role in medical technology innovation. Regularly updated content supports informed analysis of the company's market position and long-term growth trajectory within the competitive healthcare solutions landscape.

Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) has announced that Curt R. Hartman, Chair of the Board, President, and CEO, along with Todd W. Garner, Executive VP and CFO, will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 2:40 ET. Interested parties can access a live webcast through the Company’s website. CONMED specializes in providing innovative surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and general surgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) reported a 4.6% year-over-year increase in sales for Q3 2021, totaling $248.8 million. Domestic sales rose 1.6%, while international sales grew by 8.5%. Diluted EPS was $0.47, up from $0.23 in Q3 2020. Adjusted diluted EPS decreased to $0.80 from $0.88. The company adjusted its full-year revenue guidance to $1.015 billion - $1.025 billion due to ongoing pandemic impacts. Full-year adjusted diluted EPS guidance is now $3.18-$3.23, slightly revised from $3.15-$3.25.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) will release its financial results for the third quarter of 2021 on October 27, 2021, after the market closes. A conference call to discuss these results is scheduled for 4:30 p.m. ET on the same day. Participants can join via phone or through a webcast available on CONMED's website. The call will be re-playable from 7:30 p.m. ET on the same day until 7:30 p.m. ET on November 3, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) announced that Curt R. Hartman, Chair and CEO, along with CFO Todd W. Garner, will participate in a virtual fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 14, 2021, at 5:00 p.m. ET.

The session will be available for live viewing on the Company’s website, www.conmed.com, and can be replayed later.

CONMED specializes in surgical devices for minimally invasive procedures across various medical fields.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
conferences
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2021, to shareholders of record as of September 15, 2021. This decision reflects the company’s commitment to returning value to shareholders amidst ongoing challenges, including those presented by the COVID-19 pandemic. CONMED specializes in medical technology, offering surgical devices for minimally invasive procedures across various medical fields.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
dividends
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) reported a strong financial performance for Q2 2021, with sales reaching $255.2 million, a 61.7% increase year over year. Domestic revenue surged 64.2%, while international sales climbed 58.6%. Diluted EPS was $0.41, up from a loss of $0.96 in Q2 2020. The company raised its full-year revenue guidance to between $1.015 billion and $1.035 billion and adjusted EPS guidance to $3.15 to $3.25, reflecting confidence in ongoing operational improvements and market recovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) is set to report its Q2 2021 financial results on July 28, 2021, after market close. A conference call will be held at 4:30 p.m. ET to discuss the results. Interested parties can join the call by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) with passcode 7138188. The call will also be available via webcast on the CONMED website, and a recording will be accessible from 7:30 p.m. ET on the same day until August 4, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) declared a quarterly cash dividend of $0.20 per share. This dividend is payable on July 6, 2021, to shareholders of record as of June 15, 2021. CONMED specializes in medical technology, offering surgical devices for minimally invasive procedures across various specialties, including orthopedics and general surgery. For additional details, visit www.conmed.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
dividends
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) reported first-quarter 2021 financial results, highlighting a sales increase of 8.7% year-over-year to $232.7 million. Domestic revenue rose 4.3%, while international revenue surged 14.3%. Diluted EPS rose 55.0% to $0.31. The company enhanced its 2021 revenue guidance to between $1.0 billion and $1.03 billion, up from $975 million to $1.02 billion. Adjusted diluted EPS guidance is now $3.05 to $3.20, improved from $2.85 to $3.05.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.16%
Tags
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) will report its first-quarter 2021 financial results after market close on April 28, 2021. Management will host a conference call at 4:30 p.m. ET the same day to discuss the results. Investors can participate by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) using passcode 1487002. The call will also be webcast on the company's website, with a replay available one hour post-call. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags

FAQ

What is the current stock price of Conmed (CNMD)?

The current stock price of Conmed (CNMD) is $47.64 as of July 18, 2025.

What is the market cap of Conmed (CNMD)?

The market cap of Conmed (CNMD) is approximately 1.7B.
Conmed Corp

NYSE:CNMD

CNMD Rankings

CNMD Stock Data

1.66B
30.76M
0.58%
117.9%
7.45%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
LARGO